>
Switch to:

Sorrento Therapeutics Gross Profit

: $35.63 Mil (TTM As of Mar. 2021)
View and export this data going back to 2007. Start your Free Trial

Sorrento Therapeutics's gross profit for the three months ended in Mar. 2021 was $10.87 Mil. Sorrento Therapeutics's gross profit for the trailing twelve months (TTM) ended in Mar. 2021 was $35.63 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Sorrento Therapeutics's gross profit for the three months ended in Mar. 2021 was $10.87 Mil. Sorrento Therapeutics's Revenue for the three months ended in Mar. 2021 was $14.26 Mil. Therefore, Sorrento Therapeutics's Gross Margin % for the quarter that ended in Mar. 2021 was 76.25%.

Sorrento Therapeutics had a gross margin of 76.25% for the quarter that ended in Mar. 2021 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Sorrento Therapeutics was 99.13%. The lowest was 46.59%. And the median was 70.92%.


Sorrento Therapeutics Gross Profit Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Annual Data
Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Gross Profit Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.34 147.91 14.13 19.20 30.05

Sorrento Therapeutics Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Gross Profit Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.28 6.76 9.08 8.92 10.87

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Sorrento Therapeutics Gross Profit Distribution

* The bar in red indicates where Sorrento Therapeutics's Gross Profit falls into.



Sorrento Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Sorrento Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2020 is calculated as

Gross Profit (A: Dec. 2020 )=Revenue - Cost of Goods Sold
=39.986 - 9.94
=30.05

Sorrento Therapeutics's Gross Profit for the quarter that ended in Mar. 2021 is calculated as

Gross Profit (Q: Mar. 2021 )=Revenue - Cost of Goods Sold
=14.255 - 3.386
=10.87

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2021 was 6.758 (Jun. 2020 ) + 9.082 (Sep. 2020 ) + 8.924 (Dec. 2020 ) + 10.869 (Mar. 2021 ) = $35.63 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Sorrento Therapeutics's Gross Margin % for the quarter that ended in Mar. 2021 is calculated as

Gross Margin % (Q: Mar. 2021 )=Gross Profit (Q: Mar. 2021 ) / Revenue (Q: Mar. 2021 )
=(Revenue - Cost of Goods Sold) / Revenue
=10.87 / 14.255
=76.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Sorrento Therapeutics  (NAS:SRNE) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sorrento Therapeutics had a gross margin of 76.25% for the quarter that ended in Mar. 2021 => Durable competitive advantage


Sorrento Therapeutics Gross Profit Related Terms


Sorrento Therapeutics Gross Profit Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)